Logo image of DYAI

DYADIC INTERNATIONAL INC (DYAI) Stock Fundamental Analysis

NASDAQ:DYAI - Nasdaq - US26745T1016 - Common Stock - Currency: USD

1.47  -0.03 (-2%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to DYAI. DYAI was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of DYAI have multiple concerns. DYAI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DYAI has reported negative net income.
DYAI had a negative operating cash flow in the past year.
In the past 5 years DYAI always reported negative net income.
In the past 5 years DYAI always reported negative operating cash flow.
DYAI Yearly Net Income VS EBIT VS OCF VS FCFDYAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M

1.2 Ratios

With a Return On Assets value of -58.58%, DYAI perfoms like the industry average, outperforming 42.63% of the companies in the same industry.
Looking at the Return On Equity, with a value of -185.52%, DYAI is doing worse than 68.74% of the companies in the same industry.
Industry RankSector Rank
ROA -58.58%
ROE -185.52%
ROIC N/A
ROA(3y)-71.69%
ROA(5y)-53.66%
ROE(3y)-91.5%
ROE(5y)-66.09%
ROIC(3y)N/A
ROIC(5y)N/A
DYAI Yearly ROA, ROE, ROICDYAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

1.3 Margins

DYAI's Gross Margin of 64.57% is amongst the best of the industry. DYAI outperforms 81.17% of its industry peers.
In the last couple of years the Gross Margin of DYAI has grown nicely.
The Profit Margin and Operating Margin are not available for DYAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y41.45%
GM growth 5Y8.92%
DYAI Yearly Profit, Operating, Gross MarginsDYAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5K 10K 15K 20K

More info and screens

3

2. Health

2.1 Basic Checks

DYAI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DYAI has been increased compared to 5 years ago.
There is no outstanding debt for DYAI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DYAI Yearly Shares OutstandingDYAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
DYAI Yearly Total Debt VS Total AssetsDYAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

DYAI has an Altman-Z score of -8.15. This is a bad value and indicates that DYAI is not financially healthy and even has some risk of bankruptcy.
DYAI's Altman-Z score of -8.15 is on the low side compared to the rest of the industry. DYAI is outperformed by 70.16% of its industry peers.
A Debt/Equity ratio of 1.54 is on the high side and indicates that DYAI has dependencies on debt financing.
The Debt to Equity ratio of DYAI (1.54) is worse than 81.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Altman-Z -8.15
ROIC/WACCN/A
WACCN/A
DYAI Yearly LT Debt VS Equity VS FCFDYAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

DYAI has a Current Ratio of 5.15. This indicates that DYAI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of DYAI (5.15) is comparable to the rest of the industry.
DYAI has a Quick Ratio of 5.15. This indicates that DYAI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.15, DYAI is in line with its industry, outperforming 56.31% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.15
Quick Ratio 5.15
DYAI Yearly Current Assets VS Current LiabilitesDYAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for DYAI have decreased by 0.00% in the last year.
The Revenue has grown by 13.67% in the past year. This is quite good.
The Revenue has been growing by 17.40% on average over the past years. This is quite good.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.33%
Revenue 1Y (TTM)13.67%
Revenue growth 3Y21.91%
Revenue growth 5Y17.4%
Sales Q2Q%392.95%

3.2 Future

DYAI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -10.79% yearly.
DYAI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.72% yearly.
EPS Next Y23.5%
EPS Next 2Y9.2%
EPS Next 3Y-10.79%
EPS Next 5YN/A
Revenue Next Year40.98%
Revenue Next 2Y56.29%
Revenue Next 3Y21.72%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DYAI Yearly Revenue VS EstimatesDYAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
DYAI Yearly EPS VS EstimatesDYAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DYAI. In the last year negative earnings were reported.
Also next year DYAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DYAI Price Earnings VS Forward Price EarningsDYAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DYAI Per share dataDYAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

A cheap valuation may be justified as DYAI's earnings are expected to decrease with -10.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.2%
EPS Next 3Y-10.79%

More info and screens

0

5. Dividend

5.1 Amount

DYAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DYADIC INTERNATIONAL INC

NASDAQ:DYAI (2/21/2025, 8:14:48 PM)

1.47

-0.03 (-2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners17.3%
Inst Owner Change-98.13%
Ins Owners19.07%
Ins Owner Change0.54%
Market Cap43.50M
Analysts82.86
Price Target9.18 (524.49%)
Short Float %0.55%
Short Ratio1.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.21%
Min EPS beat(2)-5.58%
Max EPS beat(2)85.99%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)6.13%
Min Revenue beat(2)-62.17%
Max Revenue beat(2)74.42%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)23.4%
EPS NY rev (3m)35.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)48.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.93
P/FCF N/A
P/OCF N/A
P/B 12.75
P/tB 12.75
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.11
BVpS0.12
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.58%
ROE -185.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.57%
FCFM N/A
ROA(3y)-71.69%
ROA(5y)-53.66%
ROE(3y)-91.5%
ROE(5y)-66.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y41.45%
GM growth 5Y8.92%
F-Score3
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.15
Quick Ratio 5.15
Altman-Z -8.15
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.33%
EPS Next Y23.5%
EPS Next 2Y9.2%
EPS Next 3Y-10.79%
EPS Next 5YN/A
Revenue 1Y (TTM)13.67%
Revenue growth 3Y21.91%
Revenue growth 5Y17.4%
Sales Q2Q%392.95%
Revenue Next Year40.98%
Revenue Next 2Y56.29%
Revenue Next 3Y21.72%
Revenue Next 5YN/A
EBIT growth 1Y20.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.48%
OCF growth 3YN/A
OCF growth 5YN/A